ArticlePigment cell & melanoma research2021
Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015.
Article in Pigment cell & melanoma research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A global perspective on prognosis in acral and nonacral cutaneous melanoma: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2026Pooled it
- Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Utilizing relative survival to investigate melanoma subtypes across intersectional demographics: a Surveillance, Epidemiology, and End Results (SEER) cohort study.Skin health and disease · 2026Article
- Atypical Melanoma of the Lateral Fifth Metatarsal Shaft: A Rare Presentation With Minimal Mitotic Activity.Cureus · 2026Article
- A comparative transcriptomic analysis at single-cell resolution reveals acral melanoma features distinct from cutaneous melanoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.Pigment cell & melanoma research · 2025Article
- MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review.Journal of cancer research and clinical oncology · 2025Review
- Skin Cancer: Epidemiology, Screening and Clinical Features of Acral Lentiginous Melanoma (ALM), MelanomaJournal of Cancer · 2025Review
- A Narrative Review of the Evolution of Diagnostic Techniques and Treatment Strategies for Acral Lentiginous Melanoma.International journal of molecular sciences · 2024Review
- Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study.Acta dermato-venereologica · 2024Article
- Establishment and validation of a nomogram model for predicting the specific mortality risk of melanoma in upper limbs based on the SEER database.Scientific reports · 2024Article
- Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.Annals of surgical oncology · 2024Article
- Recent advancements in the diagnosis and treatment of acral melanoma.Journal of Zhejiang University. Science. B · 2024Review
- Management of acral lentiginous melanoma: current updates and future directions.Frontiers in oncology · 2024Review
- Differences in the demographics, incidence, and survival of palmar and plantar acral melanoma: a population-based study.Archives of dermatological research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acral lentiginous melanoma (ALM) is a rare histological subtype of cutaneous malignant melanoma that typically presents on the palms and soles. To characterize the demographic and treatment characteristics of ALM, we used the National Cancer Database (NCDB) to describe a large multi-institutional cohort of ALM patients, consisting of 4,796 ALM patients from 2004 to 2015. ALM was more likely to be diagnosed at a later stage overall compared with non-ALM cutaneous melanomas, and more likely to be thicker, ulcerated, lymph node positive, and have lymphovascular invasion and positive margins. When stratified by stage, ALM had worse survival compared with non-ALM patients, most notably in stage III patients with 5-year survival of 47.5% versus 56.7%, respectively (p < .001). In ALM patients, older age, male sex, higher comorbidity burden, increased tumor thickness and ulceration, positive lymph nodes, and positive metastasis were independently associated with lower 5-year survival. Multimodality therapy, defined as surgery in addition to systemic therapy and/or radiation therapy, was associated with higher survival in stage III patients but not in other stages. These results call for further investigation into possible treatment intensification in the ALM population in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.